Trial Profile
Zoledronic Acid in the Treatment of Breast Cancer With Minimal Residual Disease in the Bone Marrow.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Zoledronic acid (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- Acronyms MRD-1
- Sponsors Novartis
- 29 Dec 2009 Trial acronym MRD-1 identified as reported by ClinicalTrials.gov.
- 29 Dec 2009 Actual patient number (96) added as reported by ClinicalTrials.gov.
- 29 Dec 2009 Planned end date (Nov 2008) added as reported by ClinicalTrials.gov.